Straits Times Index
3,195.04 -18.61 (-0.58%) S&P 500
3,973.75 +72.39 (+1.86%) Dow
31,880.24 +618.34 (+1.98%) Nasdaq
11,535.27 +180.66 (+1.59%) BTC-USD
29,274.40 -1,096.60 (-3.61%) CMC Crypto 200
654.02 -20.86 (-3.09%)
Viatris Inc. (VTRS)
Pre-market:
| Previous close | 11.68 |
| Open | 11.74 |
| Bid | 11.40 x 4000 |
| Ask | 11.88 x 45100 |
| Day's range | 11.51 - 11.93 |
| 52-week range | 9.66 - 15.92 |
| Volume | |
| Avg. volume | 15,578,919 |
| Market cap | 14.099B |
| Beta (5Y monthly) | 1.30 |
| PE ratio (TTM) | 83.67 |
| EPS (TTM) | 0.14 |
| Earnings date | 08 Aug 2022 - 12 Aug 2022 |
| Forward dividend & yield | 0.48 (4.11%) |
| Ex-dividend date | 23 May 2022 |
| 1y target est | 16.78 |
- CNW Group
Viatris and Biocon Biologics Launch Abevmy® (Bevacizumab), Their Third Oncology Biosimilar, in Canada
Viatris Inc. and Biocon Biologics Ltd., a subsidiary of Biocon Ltd., announced today that Abevmy® (bevacizumab) is now available in Canada. Abevmy, co-developed by Viatris and Biocon Biologics, is a biosimilar to Roche's Avastin® (bevacizumab) and has been approved by Health Canada across four oncology indications.
- Motley Fool
2 Stocks That Are Ridiculously Cheap Right Now
Investors can look at the current market decline in one of two ways. Investors with long-term mindsets can find plenty of attractive opportunities in today's market. Viatris (NASDAQ: VTRS) appears to be a textbook value stock.
- Motley Fool
3 Dirt-Cheap Stocks You Can Buy Right Now
Here's why they chose BioNTech (NASDAQ: BNTX), Pfizer (NYSE: PFE), and Viatris (NASDAQ: VTRS). David Jagielski (BioNTech): Often investors discount a stock that may seem like it is punching above its weight class, on the assumption that it may struggle down the road. BioNTech's forward price-to-earnings multiple of around 3.8 certainly suggests that investors are perhaps not taking the growth stock seriously.
